Literature DB >> 8690914

LPS-dependent cyclooxygenase-2 induction in human monocytes is down-regulated by IL-13, but not by IFN-gamma.

T Endo1, F Ogushi, S Sone.   

Abstract

We investigated the effects of Th2 cell-associated cytokines, IL-4, IL-10, and IL-13, on prostaglandin (PG) production by human peripheral blood monocytes (HPBM) in terms of four parameters: PGE2 synthesis; cyclooxygenase activity; protein; and mRNA of two cyclooxygenase isozymes (cyclooxygenase-1 and cyclooxygenase-2). LPS-stimulated PGE2 synthesis and cyclooxygenase activity were suppressed by IL-4, IL-10, or IL-13. Furthermore, the LPS-dependent increase of cyclooxygenase activity in HPBM was attributable to cyclooxygenase-2 because it was inhibited by NS-398 (a cyclooxygenase-2-specific inhibitor). Western and Northern blot analyses revealed that the LPS-induced increases in cyclooxygenase-2 protein and mRNA were attenuated by the addition of IL-4, IL-10, or IL-13. In contrast, cyclooxygenase-1 protein and mRNA were hardly detected in monocytes that were incubated with or without LPS in the presence or absence of IL-4, IL-10, and IL-13. These results suggest that the reduction of LPS-induced PGE2 synthesis and cyclooxygenase activity by IL-4, IL-10, and IL-13 in HPBM are mainly due to the down-regulation of cyclooxygenase-2 selectively induced by LPS. Conversely, IFN-gamma, a Th1 cell-associated cytokine, did not affect PGE2 production and cyclooxygenase activity. These data suggest a mechanism for modulation of inflammation by the anti-inflammatory Th2 cell-associated cytokines but not a Th1 cell-associated cytokine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690914

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Fish macrophages express a cyclo-oxygenase-2 homologue after activation.

Authors:  J Zou; N F Neumann; J W Holland; M Belosevic; C Cunningham; C J Secombes; A F Rowley
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease.

Authors:  N Lügering; T Kucharzik; H Stein; G Winde; A Lügering; A Hasilik; W Domschke; R Stoll
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

3.  Importance of combined treatment with IL-10 and IL-4, but not IL-13, for inhibition of monocyte release of the Ca(2+)-binding protein MRP8/14.

Authors:  N Lügering; T Kucharzik; A Lügering; G Winde; C Sorg; W Domschke; R Stoll
Journal:  Immunology       Date:  1997-05       Impact factor: 7.397

4.  IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-gamma.

Authors:  L L Reznikov; S H Kim; J Y Westcott; J Frishman; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

5.  Interleukin (IL)-13 and IL-4 are potent inhibitors of IL-8 secretion by human intestinal epithelial cells.

Authors:  N Lügering; T Kucharzik; M Kraft; G Winde; C Sorg; R Stoll; W Domschke
Journal:  Dig Dis Sci       Date:  1999-03       Impact factor: 3.199

6.  Cytokine-mediated inflammatory hyperalgesia limited by interleukin-4.

Authors:  F Q Cunha; S Poole; B B Lorenzetti; F H Veiga; S H Ferreira
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 7.  Natural killer T cells: innate lymphocytes positioned as a bridge between acute and chronic inflammation?

Authors:  Lisa Fox; Subramanya Hegde; Jenny E Gumperz
Journal:  Microbes Infect       Date:  2010-09-17       Impact factor: 2.700

Review 8.  Regulation of T helper cell subsets by cyclooxygenases and their metabolites.

Authors:  Hong Li; Matthew L Edin; Artiom Gruzdev; Jennifer Cheng; J Alyce Bradbury; Joan P Graves; Laura M DeGraff; Darryl C Zeldin
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-11-28       Impact factor: 3.072

Review 9.  Interleukin-13: prospects for new treatments.

Authors:  C E Brightling; S Saha; F Hollins
Journal:  Clin Exp Allergy       Date:  2009-10-30       Impact factor: 5.018

10.  Treatment of uveitis with recombinant human interleukin-13.

Authors:  F G Roberge; M D de Smet; J Benichou; M F Kriete; J Raber; J Hakimi
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.